Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer's disease

Brain

Volumn 138, Issue 11, 2015, Pages 3373-3385

  Portelius, Erik ^a   Zetterberg, Henrik ^a,b   Skillbäck, Tobias ^a   Törnqvist, Ulrika ^a   Andreasson, Ulf ^a   Trojanowski, John Q ^c   Weiner, Michael W ^d   Shaw, Leslie M ^c   Mattsson, Niklas ^e   Blennow, Kaj ^f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LUND UNIVERSITY   (Sweden)

^f ROYAL SWEDISH ACADEMY OF SCIENCES   (Sweden)

Author keywords

Alzheimer's disease; biomarker; cerebrospinal fluid; mild cognitive impairment; neurogranin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; NEUROGRANIN; NRGN PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID LEVEL; COGNITION; CONTROLLED STUDY; DEMENTIA; FEMALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BRAIN; BRAIN CORTEX; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; DISEASE COURSE; LONGITUDINAL STUDY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; ORGAN SIZE; PATHOLOGY; PROGNOSIS; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CEREBRAL CORTEX; COGNITION; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROGRANIN; NEUROPSYCHOLOGICAL TESTS; ORGAN SIZE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 84945253818     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv267     Document Type: Article

References (33)

1. Alvarez-Bolado G, Rodriguez-Sanchez P, Tejero-Diez P, Fairen A, Diez-Guerra FJ. Neurogranin in the development of the rat telencephalon. Neuroscience 1996; 73: 565-80.
2. Baudier J, Deloulme JC, Van Dorsselaer A, Black D, Matthes HW. Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J Biol Chem 1991; 266: 229-37.
3. Bertoni-Freddari C, Fattoretti P, Casoli T, Caselli U, Meier-Ruge W. Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type. Anal Quant Cytol Histol 1996; 18: 209-13.
4. Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm 1996; 103: 603-18.
5. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-44.
6. Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 2015; 72: 287-94.
7. Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K. Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease?. Mol Chem Neuropathol 1996; 27: 195-210.
8. Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre-and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis 1999; 20: 431-7.
9. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987; 78: 151-64.
10. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457-64.
11. Diez-Guerra FJ. Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 2010; 62: 597-606.
12. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
13. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33: 341-55.
14. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004; 14: 11-22.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
16. Gerendasy DD, Sutcliffe JG. RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol 1997; 15: 131-63.
17. Hayashi Y. Long-term potentiation: two pathways meet at neurogranin. EMBO J 2009; 28: 2859-60.
18. Huang KP, Huang FL, Chen HC. Characterization of a 7. 5-kDa protein kinase C substrate (RC3 protein, neurogranin) from rat brain. Arch Biochem Biophys 1993; 305: 570-80.
19. Huang KP, Huang FL, Jager T, Li J, Reymann KG, Balschun D. Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J Neurosci 2004; 24: 10660-9.
20. Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-91.
21. Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 2013; 126: 365-84.
22. Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlated with cognitive decline in prodromal Alzheimer-s disease. Alzheimer-s Dement 2014. http://dx. doi. org/10. 1016/j. jalz. 2014. 10. 009.
23. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72: 578-86.
24. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001; 56: 127-9.
25. Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol 2014; 1: 534-43.
26. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008; 1147: 180-95.
27. Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci USA 2000; 97: 11232-7.
28. Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci 1990; 10: 3782-92.
29. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
30. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007; 68: 1501-8.
31. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-13.
32. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 933-44.
33. Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res 2010; 1362: 13-22.